Zimmer Biomet (ZBH) acquired CD Diagnostics, developer of immunoassays and biomarker testing to inform treatment decisions. Financial terms were not disclosed.
The companies initially partnered in 2012 to co-develop diagnostics for musculoskeletal applications, which led to marketing of the Synovasure® diagnostic test for periprosthetic joint infection. Synovasure received EU regulatory clearance in 4Q14.
CD Diagnostics can analyze synovial fluid to investigate biomarker profiles for various clinical conditions, and create diagnostic assays that inform patient care decisions. Synovasure is reportedly able to yield information on joint infection within hours of testing.
The acquisition complements ZBH’s U.S. offering, Signature Solutions™, a suite of clinical services and technologies to support hospitals and medical practices in the transition to value-based healthcare models.
Sources: Zimmer Biomet, Inc.; ORTHOWORLD Inc.
Zimmer Biomet (ZBH) acquired CD Diagnostics, developer of immunoassays and biomarker testing to inform treatment decisions. Financial terms were not disclosed.
The companies initially partnered in 2012 to co-develop diagnostics for musculoskeletal applications, which led to marketing of the Synovasure® diagnostic test for...
Zimmer Biomet (ZBH) acquired CD Diagnostics, developer of immunoassays and biomarker testing to inform treatment decisions. Financial terms were not disclosed.
The companies initially partnered in 2012 to co-develop diagnostics for musculoskeletal applications, which led to marketing of the Synovasure® diagnostic test for periprosthetic joint infection. Synovasure received EU regulatory clearance in 4Q14.
CD Diagnostics can analyze synovial fluid to investigate biomarker profiles for various clinical conditions, and create diagnostic assays that inform patient care decisions. Synovasure is reportedly able to yield information on joint infection within hours of testing.
The acquisition complements ZBH’s U.S. offering, Signature Solutions™, a suite of clinical services and technologies to support hospitals and medical practices in the transition to value-based healthcare models.
Sources: Zimmer Biomet, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.